Nodal Status--its Impact on Prognosis in Advanced Ovarian Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2011 Nov 23

PMID 22105899

Citations 8

Authors

C Bachmann

S Bachmann

T Fehm

A Staebler

S Becker

R Rothmund

C Gardanis

E M Grischke

D Wallwiener

E F Solomayer

Affiliations

Soon will be listed here.

Abstract

Purpose: Prognostic impact of nodal status or lymphadenectomy in advanced ovarian cancer is still unclear. Known best prognostic impact in advanced ovarian cancer has the residual tumor mass. The aim of this retrospective study is to examine the importance of nodal status in correlation with residual tumor mass.

Methods: One hundred and fifty-seven consecutive patients with primary stage III ovarian cancer underwent surgery between 01/2000 and 06/2007 at the Department of gynecology and obstetrics, University Hospital, Tübingen, Germany. All patients got stage-related surgery and platin-based chemotherapy. Median follow-up time was 53.5 months, and all patients were included in the study.

Results: Resection status and nodal status are significant prognostic factors in our study (P < 0.001). In FIGO III, patients without residual tumor (R0) had significant best OS and PFS independent to node status (N0/N+; P = 0.002) compared to patients with residual tumor. In contrast, node status had significant positive impact on PFS in patients without residual tumor and node negativity. With the increase in residual tumor, the influence of lymphnode metastases on prognosis is decreasing.

Conclusion: Main intention of primary surgery is R0 resection with best prognosis in advanced stages. A systematic lymphadenectomy in cases with R0 resection or residual tumor <1 cm seems to be reasonable with positive impact on prognosis. Node status has impact on prognosis in patients with negative node after R0 resection with best PFS in FIGO III. Further prospective studies had to show whether systematic lymphadenectomy in suboptimally tumor-reduced patients can improve prognosis.

Citing Articles

Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer.

He M, Lai Y, Peng H, Tong C Front Oncol. 2021; 11:646135.

PMID: 33842358 PMC: 8034395. DOI: 10.3389/fonc.2021.646135.

Prognostic importance of peritoneal lesion-to-primary tumour standardized uptake value ratio in advanced serous epithelial ovarian cancer.

Chung H, Kim J, Park N, Song Y, Cheon G Eur Radiol. 2017; 28(5):2107-2114.

PMID: 29260365 DOI: 10.1007/s00330-017-5194-0.

Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer.

Chung H, Lee M, Kim H, Kim J, Park N, Song Y Eur Radiol. 2017; 27(11):4510-4515.

PMID: 28593431 DOI: 10.1007/s00330-017-4883-z.

Incidence and Impact of Lymph Node Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment.

Bachmann C, Bachmann R, Fend F, Wallwiener D J Cancer. 2016; 7(15):2241-2246.

PMID: 27994660 PMC: 5166533. DOI: 10.7150/jca.15644.

The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Ovarian Cancer.

Eo W, Chang H, Kwon S, Koh S, Kim Y, Ji Y J Cancer. 2016; 7(3):289-96.

PMID: 26918042 PMC: 4747883. DOI: 10.7150/jca.13432.

References

Hoskins W, McGuire W, Brady M, Homesley H, Creasman W, Berman M . The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994; 170(4):974-9; discussion 979-80. DOI: 10.1016/s0002-9378(94)70090-7. View

Scarabelli C, Gallo A, Visentin M, Canzonieri V, Carbone A, Zarrelli A . Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease. Int J Gynecol Cancer. 1997; 7(1):18-26. DOI: 10.1046/j.1525-1438.1997.00418.x. View

Carnino F, Fuda G, Ciccone G, Iskra L, Guercio E, Dadone D . Significance of lymph node sampling in epithelial carcinoma of the ovary. Gynecol Oncol. 1997; 65(3):467-72. DOI: 10.1006/gyno.1997.4633. View

Benedetti Panici P, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E . Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005; 97(8):560-6. DOI: 10.1093/jnci/dji102. View

Whittemore A . Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol. 1994; 55(3 Pt 2):S15-9. DOI: 10.1006/gyno.1994.1334. View

Saygili U, Guclu S, Uslu T, Erten O, Dogan E . The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. Int J Gynecol Cancer. 2002; 12(5):438-42. DOI: 10.1046/j.1525-1438.2002.01171.x. View

Eisenkop S, Friedman R, Wang H . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998; 69(2):103-8. DOI: 10.1006/gyno.1998.4955. View

Harter P, Gnauert K, Hils R, Lehmann T, Fisseler-Eckhoff A, Traut A . Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007; 17(6):1238-44. DOI: 10.1111/j.1525-1438.2007.00931.x. View

DI RE F, Baiocchi G, Fontanelli R, Grosso G, Cobellis L, Raspagliesi F . Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecol Oncol. 1996; 62(3):360-5. DOI: 10.1006/gyno.1996.0249. View

10.

Runnebaum I, Stickeler E . Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol. 2001; 127(2):73-9. DOI: 10.1007/s004320000153. View

11.

Abe A, Furumoto H, Irahara M, Ino H, Kamada M, Naka O . The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer. J Obstet Gynaecol Res. 2010; 36(5):1023-30. DOI: 10.1111/j.1447-0756.2010.01274.x. View

12.

Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, du Bois A . Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.... Gynecol Oncol. 2007; 106(1):69-74. DOI: 10.1016/j.ygyno.2007.02.026. View

13.

Mayr D, Diebold J . Grading of ovarian carcinomas. Int J Gynecol Pathol. 2000; 19(4):348-53. DOI: 10.1097/00004347-200010000-00009. View

14.

Chan J, Urban R, Hu J, Shin J, Husain A, Teng N . The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer. 2007; 96(12):1817-22. PMC: 2359970. DOI: 10.1038/sj.bjc.6603803. View

15.

Bristow R, Tomacruz R, Armstrong D, Trimble E, Montz F . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20(5):1248-59. DOI: 10.1200/JCO.2002.20.5.1248. View

16.

Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M . Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Cancer. 1998; 83(8):1555-60. View

17.

Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S . Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006; 13(12):1702-10. DOI: 10.1245/s10434-006-9058-0. View

18.

Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T . Histological classification of ovarian cancer. Med Electron Microsc. 2003; 36(1):9-17. DOI: 10.1007/s007950300002. View

19.

Crawford S, Vasey P, Paul J, Hay A, Davis J, Kaye S . Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol. 2005; 23(34):8802-11. DOI: 10.1200/JCO.2005.02.1287. View

20.

Balbi G, Manganaro M, Monteverde A, Landino I, Franzese C, Gioia F . Ovarian cancer: lymph node metastases. Eur J Gynaecol Oncol. 2009; 30(3):289-91. View